» Articles » PMID: 37127804

Osteoporosis Treatment Gap in Patients at Risk of Fracture in Egypt: a Multi-center, Cross-sectional Observational Study

Overview
Journal Arch Osteoporos
Publisher Springer
Date 2023 May 1
PMID 37127804
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To assess the treatment gap among men and postmenopausal women presenting with a fragility fracture, and to analyze the characteristics and fracture risks of the patients presenting with an index fragility fracture.

Methods: This was a multi-center, cross-sectional, observational study. Both men and postmenopausal women, admitted with an osteoporotic fracture (whether major osteoporosis or hip fracture), were consecutively recruited for this work. The fracture risk was assessed based on their FRAX calculation prior to the index fracture. All the patients were assessed for their falls and sarcopenia risks. Blood tests for bone profile as well as DXA scan were offered to all the patients.

Results: Two hundred and thirty-six patients presenting with fragility fractures were included in this work. 70.8% were women and 29.2% were men. Mean age was 70.1 (SD = 9.2) years. Ten-year probability of fracture (without BMD) was high in 65.9% of the postmenopausal women and 40.3% of the men. 82.1% of the postmenopausal women and 100% in men identified to be eligible for osteoporosis therapy did not receive any form of osteoporosis therapy. FRAX score correlated significantly with bone mineral density assessment at both hip and spine. Falls, sarcopenia, and functional disability showed significant relation to the fracture risk.

Conclusions: There is a large treatment gap in Egyptian older adults. The recent guidelines for osteoporosis management in Egypt endorsed fracture centric approach to identify people at risk. The gap appears to be related to a low rate of osteoporosis diagnosis and lack of patient education.

Citing Articles

Enhancing collagen based nanoemulgel for effective topical delivery of Aceclofenac and Citronellol oil: Formulation, optimization, in-vitro evaluation, and in-vivo osteoarthritis study with a focus on HMGB-1/RAGE/NF-κB pathway, Klotho, and miR-499a.

Aldeeb R, Salaheldin Abdelhamid Ibrahim S, Khalil I, Ragab G, El-Gazar A, Taha A Drug Deliv Transl Res. 2024; 14(11):3250-3268.

PMID: 38502267 PMC: 11445320. DOI: 10.1007/s13346-024-01548-3.


Screening and management of osteoporosis: a survey of knowledge, attitude, and practice among healthcare professionals in Egypt-a study by the Egyptian Academy of Bone Health.

Elwakil W, El Gaafary M, Miedany Y Osteoporos Int. 2023; 35(1):93-103.

PMID: 37721557 PMC: 10786960. DOI: 10.1007/s00198-023-06914-4.


Incidence and geographic characteristics of the population with osteoporotic hip fracture in Egypt- by the Egyptian Academy of Bone Health.

Miedany Y, El Gaafary M, Gadallah N, Mahran S, Fathi N, Abu-Zaid M Arch Osteoporos. 2023; 18(1):115.

PMID: 37688741 DOI: 10.1007/s11657-023-01325-8.

References
1.
Eastell R, Rosen C, Black D, Cheung A, Murad M, Shoback D . Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society* Clinical Practice Guideline. J Clin Endocrinol Metab. 2019; 104(5):1595-1622. DOI: 10.1210/jc.2019-00221. View

2.
Johansson H, Siggeirsdottir K, Harvey N, Oden A, Gudnason V, McCloskey E . Imminent risk of fracture after fracture. Osteoporos Int. 2016; 28(3):775-780. PMC: 5338733. DOI: 10.1007/s00198-016-3868-0. View

3.
Kanis J, Svedbom A, Harvey N, McCloskey E . The osteoporosis treatment gap. J Bone Miner Res. 2014; 29(9):1926-8. DOI: 10.1002/jbmr.2301. View

4.
McCloskey E, Rathi J, Heijmans S, Blagden M, Cortet B, Czerwinski E . The osteoporosis treatment gap in patients at risk of fracture in European primary care: a multi-country cross-sectional observational study. Osteoporos Int. 2020; 32(2):251-259. PMC: 7838133. DOI: 10.1007/s00198-020-05557-z. View

5.
Compston J, McClung M, Leslie W . Osteoporosis. Lancet. 2019; 393(10169):364-376. DOI: 10.1016/S0140-6736(18)32112-3. View